Physician profile
Perth A Blake
NPI 1063505105
$1,639.44
in general payments reported to CMS, 2019-2025
27 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $12.08 · 2021: $262 · 2022: $330 · 2023: $421 · 2024: $193 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $247.64 | 2021-2025 | Airsupra, Farxiga |
| Pfizer INC. | $237.63 | 2019-2025 | |
| Glaxosmithkline, LLC. | $134.46 | 2021-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $130.54 | 2019-2022 | |
| Lilly USA, LLC | $105.49 | 2022-2024 | Mounjaro |
| Edwards Lifesciences Corporation | $71.09 | 2023-2024 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $62.53 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Abbvie INC. | $62.10 | 2019-2024 | |
| Myriad Women'S Health, INC. | $57.56 | 2023 | Myrisk |
| Shield Therapeutics INC | $49.90 | 2023-2025 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $49.63 | 2023 | Seglentis, Livalo |
| Merck Sharp & Dohme LLC | $47.25 | 2021-2025 | Gardasil 9, Capvaxive |
| Abbott Laboratories | $43.01 | 2022-2023 | Freestyle Libre 2 |
| Novo Nordisk INC | $42.59 | 2024-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $38.08 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $32.53 | 2019 | |
| Idorsia Pharmaceuticals US INC | $31.98 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $31.65 | 2024 | Loreev Xr |
| Alk-Abello, INC | $23.87 | 2022 | |
| Astellas Pharma US INC | $21.18 | 2021 | |
| Amgen INC. | $21.13 | 2021 | |
| Organon LLC | $20.20 | 2021 | |
| Exeltis, USA INC. | $18.68 | 2022 | |
| Exact Sciences Corporation | $15.61 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $15.06 | 2023 | |
| Duchesnay USA Incorporated | $14.54 | 2019 | |
| Hologic Sales and Service, LLC | $13.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perth Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.